Ra Pharma Strengthens Senior Management Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals today announced two senior management appointments, Dr. Jeffrey Johnston as Senior Vice President and Chief Medical Officer and Mr. David Lubner as Chief Financial Officer and Executive Vice President, Operations.
“2015 was a breakthrough year for Ra, which included the closing of our $59M Series B financing, expanding our investor syndicate with industry leading healthcare investors, as well as the initiation of the Phase 1 study of our synthetic peptide C5 inhibitor, RA101495,” said Doug Treco, PhD, Founder and CEO of Ra Pharmaceuticals. “We are excited to have Jeff and David join our team and build on the momentum created in 2015 as we transform Ra into a successful clinical-stage biotechnology company and move our pipeline programs forward in 2016.” RA101495 is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare hemolytic syndrome, as well as other complement-based disorders.
“2015 was a breakthrough year for Ra, which included the closing of our $59M Series B financing, expanding our investor syndicate with industry leading healthcare investors, as well as the initiation of the Phase 1 study of our synthetic peptide C5 inhibitor, RA101495,” said Doug Treco, PhD, Founder and CEO of Ra Pharmaceuticals. “We are excited to have Jeff and David join our team and build on the momentum created in 2015 as we transform Ra into a successful clinical-stage biotechnology company and move our pipeline programs forward in 2016.” RA101495 is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare hemolytic syndrome, as well as other complement-based disorders.